Category Archives: Business and Investments

Latest From Business and Investments

The Life Sciences Foundation – Telling the Story of Biotechnology

LSFTreeLogo-BTN

By the Life Sciences Foundation “If a man were permitted to make all the ballads, he need not care who should make the laws of a nation.” – Scottish politician Andrew Fletcher (1653-1716) Why History Matters Biotechnologists are in the tomorrow business. They strive to innovate, invent, and make progress. They must; survival depends on it. Biotechnologists are future-oriented. Yet, biotechnologists are also steeped in history. They swim in the past, and strive constantly to Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , ,

Partnering Launches for the International Convention

partnering-logo-btn

It’s here folks! The One-on-One Partnering™ System for this year’s BIO Business Forum® and Exhibitor Partnering has officially launched! What does that mean? If you’re registered for the event, you’ll be receiving your login credentials shortly. If you’re not registered, you should do that now, so you can get in to the system. From there, you can start building your company’s profile, search for companies, and send your targeted meeting requests. This year, we’re pleased Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

April 11th Webinar: Expanded Partnering

Join us for Part 3 of the 4 webinar series outlining NEW exhibitor booth partnering, One-on-One System enhancements, and how to get more ROI using partnering at the 2012 BIO International Convention. Unlock the Power of Partnering: Webinar & Discussion on Expanded Partnering and Tips for Partnering Success at BIO Wednesday, April 11th 11:00 am – 12:00 pm ET RSVP Here This partnering webinar will cover the following: New in 2012: Expanded Opportunities with Exhibitor Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Indices, IPOs, and New Drug Approvals – Update April 3rd 2012

Index-March-20121

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued to outperform in March, maintaining its Year-to-Date (YTD) lead of 18% vs. 12% for the S&P 500. Concentrated portfolios holding Amlyin, Regeneron, and Illumina came out even higher. For example, the Amex Biotech Index (BTK) is up 29% this year mainly because it held concentrated positions in these names. Amylin (ALMN) has doubled on the FDA approval for Bydureon and post-approval buy-out rumors. Illumina (ILMN) is up 72% Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Dealing with Rejection, the Regulatory Kind

trytry-again

The ubiquitous CRL in biotech has made its way into the news headlines again. But is the Complete Response Letter a game-changing hurdle for a biotech, or is it par for the course these days? It turns out that almost half of NDA/BLA filings get rejected by the FDA on the 1st round. However, most companies resubmit their application, and by the 2nd review 75% of drugs gain FDA approval. After heading for a 3rd Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,